Novo Nordisk stops two more ziltivekimab heart trials, HERMES and ATHENA, after July's ZEUS failure casts doubt on IL-6 inhibition in heart disease.
September 7, 2026 03:53 AM EDTUpdated September 8, 06:33 AM
Updated: Novo Nordisk cans two more trials of IL-6 heart drug for futility
Elizabeth Cairns
Senior biopharma journalist
Novo Nordisk has ended work early on two more late-stage studies of its IL-6 inhibitor ziltivekimab after the studies’ data monitoring committee determined there was …
Earlier this year, Novo said ziltivekimab failed to reduce the risk of heart attacks and strokes, diminishing expectations for…
Novartis plans Phase 3 trial of pacibekitug for CV risk reduction despite Novo Nordisk's failed ZEUS trial of ziltivekimab.…
Ziltivekimab's failure in a key trial spurred share sell-offs for Novo and other biotechs, as it suggested trouble for different…
Novo Nordisk Phase 3 ZEUS trial shows ziltivekimab missed MACE risk reduction. Operating profit outlook unchanged despite Q3…
The experimental medicine ziltivekimab didn't translate into a statistically meaningful reduction in major cardiovascular adverse…
Novo Nordisk (NVO) shares dropped about 9% today after the company reported that its experimental heart drug ziltivekimab failed…
